Clinical and imaging characteristics of supratentorial glioma with IDH2 mutation-Reference-Cited by-同舟云学术

Clinical and imaging characteristics of supratentorial glioma with IDH2 mutation

Published:2024-04-24 Issue:6 Volume:66 Page:973-981
ISSN:0028-3940
Container-title:Neuroradiology
language:en
Short-container-title:Neuroradiology

Author:

Ikeda Satoshi,Sakata Akihiko^ORCID,Arakawa Yoshiki,Mineharu Yohei,Makino Yasuhide,Takeuchi Yasuhide,Fushimi Yasutaka,Okuchi Sachi,Nakajima Satoshi,Otani Sayo,Nakamoto Yuji

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00234-024-03361-8.pdf

Reference38 articles.

1. Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol 23:1231–1251

2. Mellinghoff IK, van den Bent MJ, Blumenthal DT et al (2023) Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. https://doi.org/10.1056/NEJMoa2304194

3. Ward PS, Lu C, Cross JR et al (2013) The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288:3804–3815

4. Gross S, Cairns RA, Minden MD et al (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339–344

5. Appay R, Tabouret E, Macagno N et al (2018) IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. Neuro Oncol 20:716–718

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction to: Clinical and imaging characteristics of supratentorial glioma with IDH2 mutation;Neuroradiology;2024-04-29